NasdaqGM:SIBN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has SI-BONE's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SIBN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.8%

SIBN

4.9%

US Medical Equipment

3.9%

US Market


1 Year Return

39.6%

SIBN

21.7%

US Medical Equipment

18.5%

US Market

Return vs Industry: SIBN exceeded the US Medical Equipment industry which returned 21.7% over the past year.

Return vs Market: SIBN exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

SIBNIndustryMarket
7 Day6.8%4.9%3.9%
30 Day7.3%-0.8%-4.3%
90 Day47.2%11.4%8.1%
1 Year39.6%39.6%22.8%21.7%21.2%18.5%
3 Yearn/a72.0%67.5%38.2%29.0%
5 Yearn/a147.9%128.8%84.3%63.4%

Price Volatility Vs. Market

How volatile is SI-BONE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SI-BONE undervalued compared to its fair value and its price relative to the market?

6.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SIBN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SIBN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SIBN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: SIBN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SIBN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SIBN is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is SI-BONE forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

43.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SIBN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SIBN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SIBN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SIBN's revenue (23.7% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: SIBN's revenue (23.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SIBN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has SI-BONE performed over the past 5 years?

-8.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SIBN is currently unprofitable.

Growing Profit Margin: SIBN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SIBN is unprofitable, and losses have increased over the past 5 years at a rate of 8.9% per year.

Accelerating Growth: Unable to compare SIBN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SIBN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: SIBN has a negative Return on Equity (-42.32%), as it is currently unprofitable.


Next Steps

Financial Health

How is SI-BONE's financial position?


Financial Position Analysis

Short Term Liabilities: SIBN's short term assets ($154.5M) exceed its short term liabilities ($11.7M).

Long Term Liabilities: SIBN's short term assets ($154.5M) exceed its long term liabilities ($39.7M).


Debt to Equity History and Analysis

Debt Level: SIBN's debt to equity ratio (36.4%) is considered satisfactory.

Reducing Debt: SIBN's debt to equity ratio has reduced from 361.1% to 36.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SIBN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: SIBN has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 0.9% each year.


Next Steps

Dividend

What is SI-BONE current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SIBN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SIBN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SIBN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SIBN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SIBN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Jeff Dunn (64 yo)

12.42yrs

Tenure

US$4,185,586

Compensation

Mr. Jeffrey W. Dunn serves as Chief Executive Officer, President and Chairman at SI-Bone Inc. since its Inception in April 2008. Mr. Dunn served as President and Chief Executive Officer of Active Decisions ...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD4.19M) is above average for companies of similar size in the US market ($USD3.02M).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Dunn
Chairman12.42yrsUS$4.19m0.84%
$ 5.7m
Laura Francis
CFO & COO5.33yrsUS$2.06m0.19%
$ 1.3m
Anthony Recupero
Chief Commercial Officer4.17yrsUS$1.47m0.033%
$ 223.3k
Scott Yerby
Chief Technology Officerno datano data0.28%
$ 1.9m
Michael Pisetsky
General Counsel4.08yrsno data0.046%
$ 314.6k
Joseph Powers
Vice President of Marketing8.08yrsno datano data
W. Reckling
Chief Medical Officer & VP of Medical Affairsno datano data0.014%
$ 97.0k
Joyce Goto
VP & Corporate Controller0.17yrno datano data

4.8yrs

Average Tenure

55.5yo

Average Age

Experienced Management: SIBN's management team is considered experienced (4.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Dunn
Chairman12.42yrsUS$4.19m0.84%
$ 5.7m
Timothy Davis
Lead Independent Director1.67yrsUS$215.16k0.022%
$ 152.4k
Gregory Hinckley
Independent Director9.67yrsUS$203.05k0.45%
$ 3.1m
Jeryl Hilleman
Independent Director0.75yrUS$218.88k0%
$ 0
John Freund
Independent Director7.67yrsUS$178.75k0%
$ 0
Keith Valentine
Independent Director5.08yrsUS$187.15k0.11%
$ 744.2k
Karen Licitra
Independent Director5.08yrsUS$178.99k0%
$ 0
Ralph Rashbaum
Member of Medical Advisory Board10.67yrsno datano data
Steven Garfin
Member of Medical Advisory Board9.75yrsno datano data
Frank Phillips
Member of Medical Advisory Board9.75yrsno datano data
A. Shamie
Member of Medical Advisory Board9.75yrsno datano data
Jonathan Hyde
Member of Surgeon Advisory Boardno datano datano data

9.7yrs

Average Tenure

62yo

Average Age

Experienced Board: SIBN's board of directors are considered experienced (9.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SIBN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.


Top Shareholders

Company Information

SI-BONE, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SI-BONE, Inc.
  • Ticker: SIBN
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$679.103m
  • Shares outstanding: 28.63m
  • Website: https://si-bone.com

Number of Employees


Location

  • SI-BONE, Inc.
  • 471 El Camino Real
  • Suite 101
  • Santa Clara
  • California
  • 95050
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SIBNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2018
2K3DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2018

Biography

SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimal ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/01 00:43
End of Day Share Price2020/09/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.